NEW YORK, May 19, 2017 /PRNewswire/ --
Pre-market, Stock-Callers.com reviews these four stocks: Agenus Inc. (NASDAQ:AGEN), Athersys Inc. (NASDAQ: ATHX), Actinium Pharmaceuticals Inc. (NYSE MKT: ATNM), and AVEO Pharmaceuticals Inc. (NASDAQ: AVEO). Biotechnology companies are engaged in the research and development of biological substances, primarily for the purpose
On Thursday, shares in Lexington, Massachusetts headquartered Agenus Inc. recorded a trading volume of 605,692 shares. The stock ended the session 1.69% higher at $3.61. The Company's shares have gained 6.49% in the last one month. The stock is trading 3.04% below its 50-day moving average. Moreover, shares of Agenus, which focuses on the discovery and development of therapies that engage the body's immune system for patients suffering with cancer, have a Relative Strength Index (RSI) of 47.55.
On May 04th, 2017, Agenus provided a corporate update and reported financial results for Q1 ended March 31st, 2017. The Company reported revenue of $26.96 million for Q1 2017; R&D expense of $32.64 million; general and administrative expense of $7.77 million; and net loss of $17.1 million. In addition, cash, cash equivalents and short-term investments were $124 million as of March 31st, 2017. The free research report on AGEN is available at:
Cleveland, Ohio headquartered Athersys Inc.'s stock closed the day 1.37% lower at $1.44 with a total trading volume of 533,664 shares. The Company's shares have advanced 22.03% in the previous three months. The stock is trading 2.68% above its 50-day moving average. Additionally, shares of Athersys, which focuses on the research and development activities in the field of regenerative medicine, have an RSI of 51.21.
On May 09th, 2017, Athersys announced its financial results for the three months ended March 31st, 2017. Revenues were $1.5 million for Q1 2017; R&D expenses decreased to $5.6 million; and net loss was $5.6 million. Cash used in operating activities was $5.4 million during Q1 2017, and cash and cash equivalents balance was $31.9 million. The complimentary report on ATHX can be downloaded at:
Shares in New York-based Actinium Pharmaceuticals Inc. recorded a trading volume of 155,920 shares. The stock ended yesterday's trading session 0.76% higher at $1.32. The Company's shares have advanced 50.86% on an YTD basis. The stock is trading below its 200-day moving average by 0.30%. Furthermore, shares of Actinium Pharma, which develops targeted payload immunotherapeutics for the treatment of advanced cancers, have an RSI of 37.08.
On May 17th, 2017, Actinium Pharma announced that Dr. Richard Stone, Chief of Staff and Program Director, Acute Leukemia at the Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School, has joined the Company's Scientific Advisory Board (SAB). SAB is comprised of independent physicians considered to be key opinion leaders in the field of hematology and bone marrow transplant that contribute to and advise Actinium on the development of Iomab-B, the Company's lead asset. Visit us today and download our complete research report on ATNM for free at:
Cambridge, Massachusetts-based AVEO Pharmaceuticals Inc.'s stock finished Thursday's session 9.68% higher at $0.68 with a total trading volume of 383,245 shares. The Company's shares have advanced 17.24% in the last one month and 25.93% since the start of this year. The stock is trading above its 50-day moving average by 2.62%. Additionally, shares of AVEO Pharma, which develops targeted therapies for cancer and related diseases, have an RSI of 59.13.
On May 16th, 2017, AVEO Oncology, also AVEO Pharmaceuticals, announced the appointment of Matthew Dallas as chief financial officer, effective June 01st, 2017. In this role, Mr. Dallas will be responsible for the Company's financial strategy and management as it takes steps toward the potential commercialization of tivozanib. Mr. Dallas will also serve on the executive leadership team, which governs corporate strategy at AVEO. Get free access to your technical report on AVEO at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: email@example.com Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Angiogenesis is the process of formation of new blood vessels from pre-existing blood vessels. It ...
Aniridia is a genetic eye disorder in which the iris is partially or entirely absent. It is ...
Cachexia refers to severe muscle and fat loss, anorexia and marked weight loss due to an underlying ...View All